$-0.03 EPS Expected for BioPharmX Corporation (BPMX)

March 14, 2018 - By Migdalia James

 $ 0.03 EPS Expected for BioPharmX Corporation (BPMX)

Analysts expect BioPharmX Corporation (NYSEAMERICAN:BPMX) to report $-0.03 EPS on March, 22.They anticipate $0.06 EPS change or 66.67 % from last quarter’s $-0.09 EPS. After having $-0.05 EPS previously, BioPharmX Corporation’s analysts see -40.00 % EPS growth. The stock decreased 6.90% or $0.0216 during the last trading session, reaching $0.2914. About 9.46 million shares traded. BioPharmX Corporation (NYSEAMERICAN:BPMX) has declined 5.75% since March 14, 2017 and is downtrending. It has underperformed by 22.45% the S&P500.

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter products that address dermatology and women's health markets. The company has market cap of $37.16 million. The firm offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). It currently has negative earnings. The Company’s clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris.

More news for BioPharmX Corporation (NYSEAMERICAN:BPMX) were recently published by: Prnewswire.com, which released: “BioPharmX to Present at Oppenheimer’s 28th Annual Healthcare Conference” on March 14, 2018. Prnewswire.com‘s article titled: “BioPharmX to Present at 30th Annual ROTH Conference” and published on March 05, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: